ArticleThe American journal of cardiology2008
Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonists.
Article in The American journal of cardiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00005176 (Long QT Syndrome-Population Genetics and Cardiac Studies), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long QT Syndrome-Population Genetics and Cardiac Studies
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.Journal of cardiovascular electrophysiology · 2015Trial
- Asthma and the risk of cardiac events among patients with long QT syndrome after age 40.Heart rhythm O2 · 2025Article
- Review
- Article
- The use of attention-deficit hyperactivity disorder medications in cardiac disease.Frontiers in neuroscience · 2022Review
- Management of Congenital Long-QT Syndrome: Commentary From the Experts.Circulation. Arrhythmia and electrophysiology · 2021Review
- Asthma and stroke: a narrative review.Asthma research and practice · 2021Review
- Unmasking Long QT Syndrome in the Emergency Department: A Case Report.Clinical practice and cases in emergency medicine · 2021Article
- A case of long QT syndrome: challenges on a bumpy road.Clinical case reports · 2017Article
- Management of Patients with Long QT Syndrome.Korean circulation journal · 2016Review
- Congenital long QT syndromes: prevalence, pathophysiology and management.Paediatric drugs · 2014Review
- Asthma management in sickle cell disease.BioMed research international · 2013Review
- Sudden cardiac death due to β2-agonist therapy: is a genetic basis overlooked?Cardiovascular journal of Africa · 2012Article
- Article
- beta-Adrenoceptor inverse agonists in asthma.Current opinion in pharmacology · 2010Review
- Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism.Current opinion in pulmonary medicine · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
The clinical course and risk factors associated with beta(2)-agonist therapy for asthma have not been investigated previously in patients with the long-QT syndrome (LQTS). The risk of a first LQTS-related cardiac event due to beta(2)-agonist therapy was examined in 3,287 patients enrolled in the International LQTS Registry with QTc > or = 450 ms. The Cox proportional hazards model was used to assess the independent contribution of clinical factors for first cardiac events (syncope, aborted cardiac arrest, or sudden death) from birth through age 40. Time-dependent beta(2)-agonist therapy for asthma was associated with an increased risk for cardiac events (hazard ratio [HR] = 2.00, 95% confidence interval 1.26 to 3.15, p = 0.003) after adjustment for relevant covariates including time-dependent beta-blocker use, gender, QTc, and history of asthma. This risk was augmented within the first year after the initiation of beta(2)-agonist therapy (HR = 3.53, p = 0.006). The combined use of beta(2)-agonist therapy and anti-inflammatory steroids was associated with an elevated risk for cardiac events (HR = 3.66, p <0.01); beta-blocker therapy was associated with a reduction in cardiac events in those using beta(2) agonists (HR = 0.14, p = 0.05). In conclusion, beta(2)-agonist therapy was associated with an increased risk for cardiac events in patients with asthma with LQTS, and this risk was diminished in patients receiving beta blockers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.